# GHK-Cu topical vs injectable: what each route rests on

> GHK-Cu on skin has a small, old, mostly null human record. No human study of it alone by injection was found. What each route rests on.

Source page: https://peptioresearch.com/articles/ghk-cu-topical-vs-injectable/
Publisher: Peptio Research. Educational summary of published research, not medical advice.
Last checked against its sources: 2026-10-07
Type: Comparison

The two routes are not two columns of comparable evidence. Applied to skin, GHK-Cu has a small human record, mostly from the 1990s and 2000s, and two of its three controlled trials found no difference from the comparison treatment on objective measures. Given by injection, GHK-Cu on its own has not been studied in people in anything this review found. The one human injection study used a mixture of six active ingredients, one of them GHK-Cu, with no control group, and its abstract reports safety in four words: "Treatment was well tolerated." [1]

## The human record, route by route

### On the skin

Three controlled topical trials were found, and their results lean null. In 86 evaluable people with venous leg ulcers, a 0.4% "tripeptide copper complex" cream did no better than its vehicle; the abstract does not name the peptide, and the National Library of Medicine indexes it as glycyl-histidyl-lysine [2]. In 13 people who completed 12 weeks of skin care after CO2 laser resurfacing, every patient improved and no differences were found between the regimens with and without GHK-Cu, apart from a higher patient-rated skin quality score (P = .04) [3]. In diabetic foot ulcers, a vehicle-controlled trial reported 98.5% median closure against 60.8% for vehicle (p < 0.05); its abstract does not give the number of patients [4].

A fourth study applied a GHK-Cu cream to 10 thighs without a placebo and found increased procollagen staining in 7 of 10 [5]. One phase 2 trial of a topical GHK-Cu gel is recruiting and has no results [6].

> **Limitation.**
> The abstracts of the three controlled trials report no adverse-event data at all. That is silence, not a safety record, and it applies to the route people regard as the cautious one.

### By injection

The only human injection exposure found is Kapoor and Shome 2018: an open-label, single-arm study in which 1000 patients with hair loss were given intradermal scalp injections, meaning into the skin rather than beneath it. The formulation contained vascular endothelial growth factor, basic fibroblast growth factor, insulin-like growth factor, keratinocyte growth factor, thymosin beta-4 and "copper tripeptide-1", the cosmetic ingredient name for GHK-Cu. The authors report reduced hair fall in 83% of patients on a hair pull test and a significant increase in total hair count at one year (P = 0.002) [1].

With six actives and no control group, nothing in that result can be attributed to GHK-Cu, for benefit or for harm. A separate retrospective series of seven men had an unidentified copper peptide, mixed with minoxidil and dutasteride, tattooed into the scalp; it is not a study of GHK-Cu either [7].

> **Key point.**
> No controlled human study of GHK-Cu by injection was found, and no study of GHK-Cu alone given by injection to people. The one human injection series is an uncontrolled six-ingredient mixture [1].

## Does topical GHK-Cu get through skin?

The argument that injecting is better usually starts here. The evidence is human skin studied outside the body, not living people, and two groups disagree.

Hostynek, Dreher and Maibach applied a GHK-Cu solution to human skin ex vivo under infinite-dose conditions, meaning a reservoir that never runs out, unlike a cosmetic layer. Over 48 hours they reported copper permeating dermatomed skin, with a permeability coefficient of 2.43 × 10(-4) cm/h. They measured copper by mass spectrometry. The abstract reports no measurement of the peptide itself [8] [9].

Li and colleagues measured both the peptide and the copper and reported, over 9 hours, that "almost no peptide or copper permeated through intact human skin". Their aim was to test microneedle pretreatment, which did let both through, and they describe GHK-Cu's skin absorption as "challenging due to its hydrophilicity" [10].

The two studies differ in tissue preparation, duration and what was measured. Copper crossing the skin is not the same as GHK-Cu crossing it, and neither study says whether GHK-Cu reaches the bloodstream of a living person, or in what amount. The searches behind this page found no study measuring GHK or GHK-Cu in human blood after either route.

## Is GHK already in the blood?

A figure often quoted for plasma GHK, a fall from age 20 to age 60, appears in the opening of a 2015 review by authors at Skin Biology, a skin care company. The sentence giving it carries no citation; the next sentence cites a 1973 University of California thesis for the peptide's discovery [11]. No indexed paper giving a measured human plasma concentration was found in the abstracts searched, so this page does not repeat the numbers as findings.

In rats given copper-free GHK intravenously, "GHK was rapidly degraded to HK, which was eliminated rapidly." It is the only pharmacokinetic study found in any species, it measured copper-free GHK, and it says nothing about GHK-Cu [12].

## What has been injected into animals

Every study below used a disease or wound model. None was designed as a toxicology study. Two were wound models; none measured effects on intact skin or on hair.

| Study | Species | Route | What was reported |
|---|---|---|---|
| Maquart 1993 | Rats | Injection into implanted wound chambers | Concentration-dependent increases in collagen, DNA and protein against saline [13] |
| Swaim 1996 | Dogs, 12 English Pointers | Local injection into footpad wounds | More type I collagen at 14 days in treated wounds; the abstract says only "tripeptide-copper complex", which the National Library of Medicine indexes as glycyl-histidyl-lysine [14] |
| Fu 2015 | Rats, 24 per group | Into the knee joint | Less knee laxity at 6 weeks, no difference at 12 weeks, no difference in load, gait or histology [15] |
| Zhang 2022 | Mice | Intraperitoneal | Attenuated emphysematous changes after cigarette smoke exposure [16] |
| Ma 2020 | Mice | Intraperitoneal | Reduced bleomycin-induced lung inflammation and fibrosis [17] |
| Bian 2024 | Mice | Not stated in the abstract | Reduced lung inflammation and fibrosis in silicosis, described as "without significant systemic toxicity" [18] |

Intraperitoneal means into the abdominal cavity. Bian 2024's statement on toxicity is one sentence in a disease-model study; how toxicity was assessed is not described in the abstract. A 2026 study in ageing mice compared intraperitoneal with intranasal GHK-Cu on a memory task, but it is a preprint that has not been peer reviewed [19].

> **Evidence.**
> Everything in this section is mouse, rat or dog data. The two wound models aside, none of it concerns skin, none concerns hair, and none of it says what injection does in a person.

## How regulators treat the two routes

In the United States, FDA separates them. On its 503A list, updated 14 May 2026, GHK-Cu "except for injectable routes of administration" sits in category 1, which means under evaluation for pharmacy compounding, not approved [20]. Injectable GHK-Cu appears on FDA's safety-risks page under substances whose nominations were withdrawn, with this concern: "Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations." [21] Immunogenicity is the risk of provoking an immune response. That is a regulator's stated concern, not a measured finding. FDA says its Pharmacy Compounding Advisory Committee will consider GHK-Cu before the end of February 2027 [22].

In Australia, the Therapeutic Goods Administration and the Chief Medical Officer issued a joint statement on 19 June 2026 warning about unapproved peptide products, which "can include products containing BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295." It does not distinguish topical from injectable products. The text was read in a browser by a person and pasted into this project's records, not retrieved by the pipeline directly [23].

> **Caution.**
> The TGA statement reports serious adverse effects, including liver damage and severe allergic reactions requiring hospitalisation, associated with unapproved peptides in general. It does not attribute any of them to GHK-Cu or to any named peptide [23]. It also lists among the unknowns whether injectable products are sterile and made under aseptic conditions.

No analytical study testing injectable GHK-Cu products was found.

## What the comparison comes down to

The topical route has a few small trials, most of them null, none reporting adverse events, and laboratory skin data that disagree on whether the peptide gets through. The injectable route has a regulator's immunogenicity concern, animal wound and disease models, and one uncontrolled human mixture. Better absorption, if injection gives it, is not the same as an effect, and no human study shows injected GHK-Cu doing anything to skin or hair.

## Sources

1. Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study. Journal of Cosmetic and Laser Therapy. 2018. https://doi.org/10.1080/14764172.2018.1439965
2. Bishop JB et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. Journal of Vascular Surgery. 1992. https://doi.org/10.1067/mva.1992.37086
3. Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery. 2006. https://doi.org/10.1001/archfaci.8.4.252
4. Mulder GD et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair and Regeneration. 1994. https://doi.org/10.1046/j.1524-475X.1994.20406.x
5. Abdulghani AA et al. Effects of topical creams containing vitamin C, a copper-binding peptide cream and melatonin compared with tretinoin on the ultrastructure of normal skin: a pilot clinical, histologic, and ultrastructural study. Disease Management and Clinical Outcomes. 1998. https://doi.org/10.1016/S1088-3371(98)00011-4
6. A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Split-Wound Study of Topical GHK-Cu (Copper(II)-Peptide Complex) Gel to Accelerate Re-Epithelialization of Standardized Acute Skin Wounds in Healthy Adults. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT07437586
7. Kuceki G et al. Enhanced hair regrowth with five monthly sessions of minoxidil-dutasteride-copper peptides tattooing for androgenetic alopecia assessed by artificial intelligence and blinded evaluators. JAAD International. 2025. https://doi.org/10.1016/j.jdin.2025.01.012
8. Hostynek JJ, Dreher F, Maibach HI. Human skin retention and penetration of a copper tripeptide in vitro as function of skin layer towards anti-inflammatory therapy. Inflammation Research. 2010. https://doi.org/10.1007/s00011-010-0214-4
9. Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflammation Research. 2011. https://doi.org/10.1007/s00011-010-0238-9
10. Li H et al. Microneedle-Mediated Delivery of Copper Peptide Through Skin. Pharmaceutical Research. 2015. https://doi.org/10.1007/s11095-015-1652-z
11. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015. https://doi.org/10.1155/2015/648108
12. Endo T, Miyagi M, Ujiie A. Simultaneous determination of glycyl-L-histidyl-L-lysine and its metabolite, L-histidyl-L-lysine, in rat plasma by high-performance liquid chromatography with post-column derivatization. Journal of Chromatography B, Biomedical Sciences and Applications. 1997. https://doi.org/10.1016/s0378-4347(96)00460-4
13. Maquart FX et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. The Journal of Clinical Investigation. 1993. https://doi.org/10.1172/JCI116842
14. Swaim SF et al. Effect of locally injected medications on healing of pad wounds in dogs. American Journal of Veterinary Research. 1996. https://pubmed.ncbi.nlm.nih.gov/8669775/
15. Fu SC. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. Journal of Orthopaedic Research. 2015. https://doi.org/10.1002/jor.22831
16. Zhang Q. Glycyl-L-histidyl-L-lysine-Cu(2+) attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway. Frontiers in Molecular Biosciences. 2022. https://doi.org/10.3389/fmolb.2022.925700
17. Ma WH. Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways. Life Sciences. 2020. https://doi.org/10.1016/j.lfs.2019.117139
18. Bian Y. The glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6. Redox Biology. 2024. https://doi.org/10.1016/j.redox.2024.103237
19. Mazzola J. Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs. Research Square. 2026. https://doi.org/10.21203/rs.3.rs-9520102/v1
20. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, updated May 14, 2026. U.S. Food and Drug Administration. 2026. https://www.fda.gov/media/94155/download
21. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
22. Meeting of the Pharmacy Compounding Advisory Committee (to be scheduled before the end of February 2027). U.S. Food and Drug Administration. 2026. https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee
23. Concerns regarding the public health risks associated with unapproved peptide products. Therapeutic Goods Administration. 2026. https://www.tga.gov.au/news/media-releases/concerns-regarding-public-health-risks-associated-unapproved-peptide-products
